Published: Monday, Jul. 1, 2013 – 6:13 am
ALISO VIEJO, Calif., July 1, 2013 —/PRNewswire/ — Avanir Pharmaceuticals,Inc. (NASDAQ: AVNR) today announced completion of patient enrollment in the company’s phase II, placebo controlled study testing three doses of AVP-923 for the treatment of central neuropathic pain in multiple sclerosis.Top-line results from this study are expected in the fourth calendar quarter of 2013.
“Final completion of enrollment in PRIME is an important milestone in the AVP-923 development pathway,” said Joao Siffert, MD, chief scientific officer at Avanir. “We are looking forward to the results from this study to help guide design of our phase III studies in neuropathic pain.”
About the PRIME Study The objectives of the PRIME (Pain Research In Multiple Sclerosis) study are to evaluate the safety, tolerability, and efficacy of AVP-923 for the treatment of central neuropathic pain in patients with multiple sclerosis.
READ MORE
..
USE OUR SHARE LINKS at the top of this page – to provide this article to others
REMAIN up to date with MS News and Education
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
